Page last updated: 2024-11-07

l 687414

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 687414: RN given refers to (3S-cis)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125556
CHEMBL ID165945
SCHEMBL ID4261650
MeSH IDM0223737

Synonyms (13)

Synonym
l 687414
(3s,4s)-3-amino-1-hydroxy-4-methylpyrrolidin-2-one
CHEMBL165945 ,
(3s,4s)-3-amino-1-hydroxy-4-methyl-pyrrolidin-2-one
bdbm50280796
cis-4-methyl-ha-966
2-pyrrolidinone, 3-amino,1-hydroxy-4-methyl-, (3s-cis)-
l-687,414
l 687,414
132695-96-6
SKYSFPFYQBZGDC-IMJSIDKUSA-N
SCHEMBL4261650
DTXSID00157720

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The three infusion dosing regimens gave mean plasma levels over the 4 h of 11, 25 and 61 micrograms/ml plasma, respectively."( The neuroprotective effect of the glycine site antagonist 3R-(+)-cis-4-methyl-HA966 (L-687,414) in a rat model of focal ischaemia.
Gill, R; Hargreaves, RJ; Kemp, JA, 1995
)
0.29
" In contrast, L-687,414 did not increase limbic CMRglc, nor evoke vacuolation when given in the neuroprotective dose-regime or at the higher dosage rate."( Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology.
Hargreaves, RJ; Hill, RG; Rigby, M; Smith, D, 1993
)
0.29
" LTP was effectively abolished in a separate group of rats treated with an MK-801 dosing regimen (0."( L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective.
Hill, RG; Kemp, JA; Marshall, GR; Priestley, T, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (61.54)18.2507
2000's1 (7.69)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.68 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]